A strain producing methylmeleagrin compound and fermentation production method and application thereof
Methylmeleagrin compound prepared by isolation and fermentation from the mangrove forest in Wenchang, Hainan has solved the problem of insufficient research on production methods and activity in the prior art, achieved effective inhibition of a variety of cancer cells, and demonstrated its potential in tumor treatment .
Patent Information
- Application Number
- CN202411111570.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-08-14
AI Technical Summary
In the prior art, there are few researches on the production methods and activities of Methylmeleagrin compounds, and their application potential in the treatment of multidrug-resistant bacteria and tumor cells has not been fully developed.
Penicillium sp. OUCMDZ-YLY01, a strain of Penicillium sp. that efficiently produces Methylmeleagrin, was isolated and identified from the Wenchang mangrove nature reserve in Hainan. The compound was prepared by fermentation method and cultured with L-histidine and L-tryptophan. The strain was activated and fermented by the base, combined with ethyl acetate extraction and gel column separation, and obtained the pure Methylmeleagrin.
Achieve efficient production of Methylmeleagrin compounds and demonstrate its significant inhibitory effect on human lung, breast, colorectal and liver cancer cells, demonstrating its potential as a cell cycle blocker and apoptosis inducer, and has the application of developing therapeutic drugs. prospect.
Smart Images

Figure CN118638650B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of marine microorganisms and medical technology, and in particular to a Penicillium strain producing a methylmeleagrin compound from the Wenchang Mangrove Nature Reserve in Hainan, as well as a fermentation production method and application thereof. Background Art
[0002] The mangrove ecosystem is a transition between the marine ecosystem and the wetland ecosystem. It is located at the junction of land and ocean. Because it is periodically inundated by seawater, it has the characteristics of both marine and terrestrial ecosystems. In addition to the characteristics of high temperature, humidity, and long exposure to sunlight, it also has the characteristics of soil salinization, swamping, strong acidity, and high organic matter content.
[0003] The soil at the roots of mangroves is acidic and high in organic matter, so it contains rich marine fungal resources, and its secondary metabolites have great potential for marine drug development.
[0004] Marine fungi of mangroves often grow in the roots, stems, branches submerged in seawater and the soil attached to them. Fungi in the root soil of mangroves have a high decomposition ability and can convert organic matter in mangrove fallen leaves into inorganic matter for reuse by plants, while producing abundant secondary metabolites. At present, people have not only discovered extracellular degradation enzymes with ecological significance from mangrove fungi, but also isolated a large number of active secondary metabolites from mangrove fungi. The former mainly includes cellulase, xylanase, pectinase and plant amylase. The discovery and use of these extracellular degradation enzymes have strongly promoted the development of modern biotechnology; the latter are mostly used in the pharmaceutical field, such as the development of antibacterial, anticancer, antioxidant and anti-diabetic drugs, and are also used in the research and development of biological pesticides and nutritional products.
[0005] Isobutyric acid alkaloids are a class of metabolites mainly produced by the fungus Penicillium. The structure of this class of compounds is composed of histidine, tryptophan and isovaleric acid residues. The compound Methylmeleagrin (structure shown in formula (I)) is an alkaloid containing a unique dihydroindole spiroaminoamide framework. It was first discovered in 1984. Penicillium Meleagrinum It was first discovered in the secondary metabolites of Chem. Pharm. Bull ., 1984).
[0006] (I)
[0007] Methylmeleagrin can be used as a novel FabI (bacterial enoyl-acyl protein reductase) inhibitor with the potential to treat multidrug-resistant bacteria (Chang, JZ Plos One, 2013). However, there are few studies on the production methods and activities of Methylmeleagrin compounds. Summary of the invention
[0008] The first object of the present invention is to provide a strain that can efficiently produce Methylmeleagrin compounds.
[0009] The second object of the present invention is to provide a simple and efficient method for producing Methylmeleagrin compounds by fermentation using the above strains.
[0010] The third object of the present invention is to provide the use of the above-mentioned strain to produce Methylmeleagrin compounds by fermentation in the preparation of drugs for treating human lung cancer, breast cancer, colorectal cancer and liver cancer.
[0011] The specific technical scheme of the present invention is as follows: The present invention provides a strain that produces Methylmeleagrin, which is isolated and purified from a root mud sample of the Wenchang Mangrove Nature Reserve in Hainan Province and named Penicillium ( Penicillium sp.) OUCMDZ-YLY01, which was deposited in the China General Microbiological Culture Collection Center (CGMCC) on July 15, 2024, with the deposit number CGMCC No. 41464. The ITS DNA sequence length of the strain is 556 bp, as shown in SEQ No. 1.
[0012] In another aspect, the present invention provides a method for producing a Methylmeleagrin compound by fermentation using the above strain, comprising the following steps:
[0013] (1) Strain activation: Penicillium sp. OUCMDZ-YLY01 strain was inoculated on a PDA plate and cultured for 5-7 days, then the spores of the strain on the plate were picked for activation. The activation conditions were: fungal medium 2#, 28°C, shaking speed 180±10 rpm, and culture for 3 days;
[0014] (2) Strain fermentation: Take the activated strain and inoculate it into fungal medium No. 2 containing L-histidine and L-tryptophan, pH 3.5, and ferment it for 23 days at a fermentation temperature of 28°C to obtain a fermentation culture;
[0015] (3) separating the fermentation liquid and mycelium in the fermentation culture, and extracting the fermentation liquid with ethyl acetate to obtain a crude fermentation extract;
[0016] (4) The crude fermentation extract is separated twice using a gel column, and the resulting component is pure Methylmeleagrin.
[0017] In step (2), the activated strain is inoculated and fermented at an inoculation rate of 5% by volume.
[0018] The fungus 2# culture medium comprises: 1% monosodium glutamate, 2% mannitol, 2% maltose, 0.05% KH2PO4, 1% glucose, 0.1% corn steep liquor, 0.03% MgSO4·7H2O, 0.3% yeast extract and seawater. The initial pH value of the culture medium is 6.5±0.2, and concentrated HCl is added to adjust the pH value to 3.5.
[0019] Furthermore, the fungus 2# culture medium used in steps (1) and (2) is sterilized by high pressure sterilization at 121°C for 20 min.
[0020] In step (2), the activated strain is inoculated and fermented at an inoculation rate of 5% by volume.
[0021] In step (2), the final concentration of L-histidine and L-tryptophan added was 200 mg / L.
[0022] In a third aspect, the present invention provides the use of the Methylmeleagrin compound produced by the above-mentioned strain as a cell cycle inhibitor and tumor cell apoptosis inducer, which has the further use of preparing drugs for treating human lung cancer, human breast cancer, colorectal cancer, and liver cancer.
[0023] The invention has the beneficial effects as follows: the invention provides a strain for efficiently producing Methylmeleagrin, and provides a simple and efficient process for producing Methylmeleagrin by fermentation using the strain, providing raw materials for in-depth activity evaluation and structural modification of isoniacin compounds; the Methylmeleagrin compound produced by the strain of the invention has a good inhibitory effect on four tumor cells, namely, human lung cancer cell line A549, human breast cancer cell line MCF-7, human colon cancer cell line HCT-116, and human liver cancer cell line HepG2, proving that the Methylmeleagrin compound can block the cell cycle of HepG2 and induce cell apoptosis, and can be used as an application for developing drugs for treating human lung cancer, breast cancer, colorectal cancer, and liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 yes Penicillium Strain morphology of sp. OUCMDZ-YLY01.
[0025] Figure 2 yes Penicillium Phylogenetic tree of sp. OUCMDZ-YLY01.
[0026] Figure 3 This is the H NMR spectrum of Methylmeleagrin (pyridine - d 5 , 500 MHz).
[0027] Figure 4 This is the C NMR spectrum of Methylmeleagrin (pyridine - d 5 , 125 MHz).
[0028] Figure 5 It is a line graph of cell viability of HepG2 cells treated with different concentrations of Methylmeleagrin.
[0029] Among them, the left figure is the cell inhibition rate curve of HepG2 cells treated with different concentrations of Methylmeleagrin for 12 hours; the right figure is the cell inhibition rate of HepG2 cells treated with different concentrations of Methylmeleagrin for 24 hours.
[0030] Figure 6 These are photos of HepG2 cells observed under an optical microscope after being treated with different concentrations of Methylmeleagrin for 24 hours. DETAILED DESCRIPTION
[0031] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments.
[0032] The experimental methods in the following examples are conventional methods unless otherwise specified; the experimental reagents used in the following examples are commercially available products unless otherwise specified.
[0033] Example 1: Isolation, purification and identification of strains
[0034] A Penicillium strain producing a methylmeleagrin compound originating from the Wenchang Mangrove Nature Reserve in Hainan Province is isolated and purified from a root mud sample in the Wenchang Mangrove Nature Reserve in Hainan Province.
[0035] 1. Sample Collection
[0036] The samples were 14 soil samples collected from the roots of plants such as Bruguiera gymnorrhiza, Aconitum carmichaelii, Prunus elata, Acanthus sinensis and Sonneratia ovalifolia in the Wenchang Mangrove Nature Reserve in Hainan. After collection, they were immediately placed in sterile sealed bags, frozen and transported to the laboratory, and stored in a -20°C refrigerator.
[0037] 2. Sample processing
[0038] The soil samples were separated by gradient dilution method. 1 g of sample was weighed in a sterile environment and surface sterilized with 75% ethanol. The sample was then rinsed with sterile seawater for several times and ground into a homogenate in a mortar. The supernatant was diluted with sterile seawater into three gradients of 0.1 g / mL, 0.01 g / mL, and 0.001 g / mL.
[0039] 3. Isolation and purification of strains
[0040] PDA medium (natural pH value) was used to isolate and culture microorganisms. First, 0.2 mL of sample solution with different dilution ratios was taken with a sterile pipette and added to the PDA medium. Then, a sterilized coating rod was used to spread the solution evenly. After the bacterial solution penetrated into the medium, it was placed in a 28 ℃ constant temperature incubator and inverted for 4-7 days.
[0041] The plate streak method is used to purify the strain, and the growth of the plate strain is observed. When a single colony appears, the streak culture can be carried out. The specific method of plate streak is: Use the outer flame of the alcohol lamp to burn the inoculation loop. After sufficient cooling, scrape the single colony from the plate, and use the inoculation loop to make a zigzag streak on the agar plate. This operation needs to be performed in a sterile area near the flame of the alcohol lamp. After the inoculation is completed, the strain number, name and date are marked on the bottom of the culture dish, and then it is placed in a 28 ℃ constant temperature incubator for inverted culture. If the strain cannot be purified by streaking once, a second streak operation is required until the strain is completely purified.
[0042] 4. Preservation of strains
[0043] Slant preservation: The purified strains were inoculated into slant PDA medium using the zigzag streaking method. After the strains grew to maturity, they were stored in a 4°C refrigerator. Three parallel cultures were set up for each strain.
[0044] Glycerol tube cryopreservation: Use PDA liquid medium (add 20% glycerol) as cryopreservation liquid to cryopreserve the purified strain. Take 1 mL of cryopreservation liquid into a cryopreservation tube and sterilize it. After cooling, scrape an appropriate amount of mycelium of the strain on the agar plate into a cryopreservation tube and store it in a -80 ℃ refrigerator.
[0045] 5. Identification of strains
[0046] The strains were identified by combining morphology and molecular biology. First, the external phenotypic characteristics of the strains were photographed and archived. Figure 1As shown. The strain has the following morphological characteristics: the aerial hyphae are short and white or green; the microscopic morphology of the insert under a 400x microscope shows that the aerial hyphae are broken into spores, which are spherical and smooth. The primer sequences ITS1 (5'-TCCGTAGGTGAACCTGCGG -3') and ITS4 (5'-TCCTCCGCTTATTGATATGC - 3') were used to amplify the ITS DNA sequence of the strain. The total DNA of the strain was extracted as a template for PCR amplification, and the length of the ITS DNA sequence of the strain was 556 bp (as shown in SEQ No. 1). After ITS sequence alignment, the strain was identified as Penicillium ( Penicillium sp.) OUCMDZ-YLY01, with a deposit number of CGMCC No. 41464. The phylogenetic tree of the strain is shown in Figure 2 shown.
[0047] Example 2: Method for producing Methylmeleagrin compound by fermentation using strains
[0048] 1. Preparation of total crude extract
[0049] (1) Take a small amount of Penicillium sp. OUCMDZ-YLY01 strain mycelium was inoculated on a PDA plate (200 g of potatoes were added to each liter of water and cooked, and the potato water was filtered to obtain 20 g of glucose and 15 g of agar per liter of potato water, with a natural pH), and then the strain spores were picked for activation after static culture for 5-7 days. The activation conditions were: fungal medium 2#, 28°C, shaking speed 180±10 rpm, and culture for 3 days;
[0050] The fungus 2# culture medium comprises: 1% monosodium glutamate, 2% mannitol, 2% maltose, 0.05% KH2PO4, 1% glucose, 0.1% corn steep liquor, 0.03% MgSO4·7H2O, 0.3% yeast extract and seawater. The initial pH value of the culture medium is 6.5±0.2, and concentrated HCl is added to adjust the pH value to 3.5.
[0051] (2) Take the activated bacterial liquid and inoculate it into a 1-L conical flask at a volume ratio of 5%. Each flask contains 300 mL of fungal 2# liquid culture medium (L-histidine and L-tryptophan are additionally added to make the final concentration of 200 mg / L), totaling 81 L. Place it in a 28°C environment for static culture. After 23 days of culture, the fermentation culture is obtained.
[0052] (3) The fermentation liquid and mycelium in the fermentation culture were separated. An equal volume of ethyl acetate was added to the fermentation liquid layer and extracted three times. The organic phase was taken and concentrated using a rotary evaporator to obtain 30 g of crude extract of the fermentation liquid layer.
[0053] 2. Separation and purification
[0054] The crude extract was separated by Sephadex LH-20 gel column chromatography, with the mobile phase (CH2Cl2: CH3OH = 1:1). Each 100 mL was collected and combined into one component, and then evaporated to dryness using a rotary evaporator, resulting in a total of 12 components (Fr.1 to Fr.12). The Fr.5 component was taken and separated again by Sephadex LH-20 gel column chromatography, using CH3OH as the mobile phase. Each 50 mL was collected and combined into one component, and then evaporated to dryness using a rotary evaporator, resulting in a total of 5 components (Fr.5-1 to Fr.5-5). Component Fr.5-5 was a pure product and was identified as the compound Methylmeleagrin.
[0055] 3. Structural Elucidation
[0056] The compound extracted and separated by the present invention is analyzed by various modern spectral techniques such as NMR and HRESIMS, thereby confirming that the structure of the compound in the present invention is as shown in Formula I.
[0057] Compound Methylmeleagrin: pale yellow amorphous powder, positive ion mass spectrometry ESI-MS m / z The quasi-molecular ion peak [M+H] is given at 448.2 + , indicating that the molecular weight of the compound is 447, combined with the compound 13 C, 1 The molecular formula deduced by H-NMR is: C 24 H 25 N5O4, the degree of unsaturation is 15. Its UV spectrum is UV (MeOH) [ λmax ( logε ): 199.2 (2.40), 229.8 (1.50), 285.4 (0.55), 346.3 (1.50) nm]. And the optical rotation value of the compound is [ α ] D 25 -44.9( c 0.1, CH3OH), and literature review showed that the compound was consistent with Methylmeleagrin reported in the literature, so the compound was determined to be Methylmeleagrin. 1 H and 13 C NMR nuclear magnetic resonance spectrum data are shown in Table 1, and the relevant nuclear magnetic resonance spectra for structural identification are shown in Figure 3 and Figure 4 .
[0058] Table 1 NMR data of compound Methylmeleagrin (1 H 500MHz, 13 C 125 MHz, pyridine - d 5,TMS, δ ppm)
[0059]
[0060] Example 3: In vitro antitumor activity
[0061] The in vitro anti-tumor activity experiment of the Methylmeleagrin compound prepared by the present invention adopts the MTT method and the CCK-8 method.
[0062] MTT method: Human lung cancer cell line A549, human breast cancer cell line MCF-7, human colorectal cancer stem cell P6C, human T lymphocyte leukemia cell Jurkat, leukemia cell line K562, human myeloid leukemia cell HL-60, human colon cancer cell HCT-116, and human liver cancer cell HepG2 in the logarithmic growth phase were inoculated in a 96-well plate at a cell density of 5000 cells / well and cultured in a constant temperature incubator at 37 ℃ and 5% CO2. After 24 hours, 10 μL of Methylmeleagrin compound samples of different concentrations were added to the 96-well plate to make the final volume of the solution in the plate 200 μL. After continuing to culture in the incubator for 72 hours, 20 μL of MTT solution was added and continued to incubate. After 6 hours, the plates were taken out and the absorbance (OD value) at 570 nm was detected by a microplate reader to calculate the inhibition rate (IR%).
[0063] CCK-8 method: Cell culture and sample preparation are the same as MTT method, suitable for suspension cells (leukemia cell line K562). Add the prepared sample to the cell plate, set up positive and blank controls, and culture in a constant temperature incubator for 72 hours. After 72 hours, add 10 μL of CCK-8 solution to the well containing the sample, continue to culture in a constant temperature incubator for 6 hours, use a microplate reader to detect the absorbance (OD value) at 570 nm, and calculate the inhibition rate (IR%).
[0064] Each sample to be tested was set up with five concentration gradients during the test process, and three replicate wells were set up as parallel experiments, which were expressed as standard deviation (SD) in the experimental results. The formula for calculating the inhibition rate of the sample to be tested on tumor cell growth is: inhibition rate = [control group OD value - drug group OD value] / control group OD value × 100%, half inhibition concentration IC 50 The values were calculated using the Logit method and the results are shown in Tables 2 and 3.
[0065] Table 2 Inhibition rate (%) and IC of compounds on various cell lines 50 (μM)
[0066]
[0067] Table 3 Inhibition rate (%) and IC50 (μM) of the compounds on various cell lines
[0068]
[0069] The results showed that Methylmeleagrin had good inhibitory activity against A549, MCF-7, HCT-116 and HepG2 solid tumor cells. 50 The values are 1.84, 0.82, 1.53 and 1.56 μM respectively; the present invention provides a lead compound for developing new anti-tumor drugs.
[0070] Example 4: Experiment on blocking HepG2 cell cycle and inducing cell apoptosis
[0071] The Methylmeleagrin compound prepared by the invention is used for research on blocking HepG2 cell cycle and inducing cell apoptosis.
[0072] Methylmeleagrin can inhibit the viability of HepG2 cells in a concentration-dependent manner. Figure 5 The inhibitory activity IC of Methylmeleagrin on HepG2 cells for 24 h was obtained based on the activity data. 50 is 2.8 μM.
[0073] Microscope observation method: The normal control group, that is, HepG2 cells that were not treated with compounds, showed vigorous cell growth, regular morphology, clear cell outlines, good wall adhesion, and uniform cell size. After being treated with compounds of different concentrations, the experimental group showed that the HepG2 cells became round in morphology, suspended in cells, poor wall adhesion, and severe cell fragmentation. With the increase of compound concentration, the number of live cells attached to the wall was significantly reduced, and the number of dead cells and suspended cells was significantly increased. The results are as follows Figure 6 According to the effect of different concentrations of Methylmeleagrin on HepG2 cell viability, 2.5, 5, 10, 20, and 40 μM were selected as the test concentrations for cell cycle and cell apoptosis.
[0074] Cell cycle detection method: HepG2 cells in the logarithmic growth phase were cultured at a rate of 1×10 5 / well were inoculated into 6-well plates. When the cells grew to 75%-85% of the culture dish, they were treated with 2.5, 5, 10, and 20 µM Methylmeleagrin for 24 h. After digestion, the cells were transferred to 1.5 mL centrifuge tubes and centrifuged at 5,000 rpm for 5 min. The supernatant was discarded, 500 µL of PBS was added for washing, and centrifuged again. 400 µL of 70% ethanol (pre-cooled) was accurately added to each tube, and the cells were fixed at 4 °C for 12 h. The cells were centrifuged at 2,000 rpm for 5 min, and the cells were resuspended with 100 μL RNase A and 400 μL PI. The cells were incubated at room temperature in the dark for 30 min, transferred to flow tubes, and the cell DNA content was detected by flow cytometry.
[0075] Flow cytometry analysis showed that as the concentration of Methylmeleagrin increased, the number of cells blocked in the G2 / M phase continued to increase, and its content increased from 29.538% to 81.569%. Therefore, it can be considered that Methylmeleagrin can induce HepG2 cell cycle arrest, blocking in the G2 / M phase, and the blocking effect of Methylmeleagrin on G2 / M phase cells is dose-dependent. The specific results are shown in Table 4.
[0076] Table 4 Blockade results of cells treated with different concentrations of Methylmeleagrin (%)
[0077]
[0078] According to the above experimental data analysis, Methylmeleagrin can cause HepG2 cells to arrest in the G2 / M phase. The effects of different concentrations of Methylmeleagrin on HepG2 cell apoptosis were compared. HepG2 cells were treated with different concentrations of Methylmeleagrin for 24 h, and cells were treated with Annexin V / PI double staining. The results of apoptosis detection by flow cytometry are shown in Table 5.
[0079] Table 5 Effect of Methylmeleagrin treatment on apoptosis rate of HepG2 cells
[0080]
[0081] Annexin V-FITC / PI double staining method: HepG2 cells in the logarithmic growth phase were plated at 1×10 5 / well were inoculated into 6-well plates. When the cells grew to 75%-85% of the culture dish, they were treated with 5, 10, 20, and 40 μM Methylmeleagrin for 24 h, and TE was added to digest the cells (200 μL / well). After digestion, the cells were transferred to a 1.5 mL centrifuge tube using a pipette, centrifuged at 5000 rpm for 5 min, and the supernatant was discarded. 500 μL PBS was added to each tube to resuspend the cells, and the supernatant was discarded again after centrifugation. 195 μL of 1× binding buffer was accurately added to each tube, the cells were vortexed, and Annexin V / PI staining solution (3 μL) and PI staining solution (2 μL) were accurately added. Incubate at room temperature in the dark for 30 min. The cell suspension was slowly injected into the bottom of the flow tube and immediately detected by flow cytometry for the number of apoptosis, where Annexin V was displayed as green fluorescence and PI was displayed as red fluorescence.
[0082] The results of data analysis showed that compared with the cell apoptosis rate in the group without drug addition, Methylmeleagrin induced early apoptosis of cells. The number of early apoptotic cells increased with the increase of compound concentration, showing a dose-dependent relationship, and the effect was more obvious.
Claims
1. A strain producing Methylmeleagrin, characterized in that: The strain is named Penicillium ( Penicillium sp. )OUCMDZ-YLY01, with a deposit number of CGMCC No. 41464. The ITS DNA sequence of the strain is shown in SEQ No.
1. The structure of the compound Methylmeleagrin is shown in formula (I): (I)。 2. A method for producing a methylmeleagrin compound by fermentation using the strain according to claim 1, characterized in that: The following steps are involved: (1) Strain activation: Take Penicillium ( Penicillium sp.) OUCMDZ-YLY01 strain was inoculated on a PDA plate and cultured for 5-7 days, then the spores of the strain on the plate were picked for activation. The activation conditions were: fungal medium 2#, 28°C, shaking speed 180±10 rpm, and culture for 3 days; (2) Strain fermentation: Take the activated strain and inoculate it into fungal medium No. 2 at pH 3.5 containing L-histidine and L-tryptophan, and ferment it for 23 days at a fermentation temperature of 28°C to obtain a fermentation culture; (3) separating the fermentation liquid and mycelium in the fermentation culture, and extracting the fermentation liquid with ethyl acetate to obtain a crude fermentation extract; (4) Separation and purification: The fermentation crude extract was separated by Sephadex LH-20 gel column chromatography, using CH2Cl2: CH3OH = 1:1 as the mobile phase. 100 mL of the collected extracts were combined into one component and evaporated to dryness using a rotary evaporator, obtaining a total of 12 components: Fr.1 to Fr.
12. Component Fr.5 was taken and separated again by Sephadex LH-20 gel column chromatography using CH3OH as the mobile phase. 50 mL of the collected extracts were combined into one component and evaporated to dryness using a rotary evaporator, obtaining a total of 5 components: Fr.5-1 to Fr.5-5. Component Fr.5-5 is pure Methylmeleagrin, and the structure of the compound Methylmeleagrin is shown in formula (I): (I)。 3. The method for producing a Methylmeleagrin compound according to claim 2, wherein: The fungus 2# culture medium comprises: 1% monosodium glutamate, 2% mannitol, 2% maltose, 0.05% KH2PO4, 1% glucose, 0.1% corn steep liquor, 0.03% MgSO4·7H2O, 0.3% yeast extract and seawater. The initial pH value of the culture medium is 6.5±0.2, and the pH value is adjusted to 3.5 by adding concentrated HCl.
4. The method for producing a Methylmeleagrin compound according to claim 2, characterized in that: In step (2), the activated strain is inoculated and fermented at an inoculation rate of 5% by volume.
5. The method for producing a Methylmeleagrin compound according to claim 2, wherein: In step (2), the final concentration of L-histidine and L-tryptophan added was 200 mg / L.
6. The method for producing a Methylmeleagrin compound according to claim 2, wherein: The fungus 2# culture medium used in steps (1) and (2) was sterilized by high pressure sterilization at 121°C for 20 min.
7. Use of the Methylmeleagrin compound produced by the method of any one of claims 2 to 6 for preparing drugs for treating human lung cancer, breast cancer, colorectal cancer and liver cancer.
Citation Information
Patent Citations
Application of class of indole alkaloids to preparation of marine biofouling prevention coating material
CN102757677A
Chemical classification method for penicillium species based on mass spectrometry and marker thereof
KR1020140017941A
